Driving biopharma and medtech progress forward via innovation, capital, and collaborations.
A French chemist and microbiologist, his transformative contributions to germ theory, vaccination, and pasteurization fundamentally changed medical practice
GenBio will hold meetings with pharmaceutical and biotech leaders in Singapore to explore its scientific platform and strategic prospects.
In the realm of observation, fortune favors only the mind that is prepared.”— Louis Pasteur
ALISO VIEJO, CA, UNITED STATES, August 1, 2026 /EINPresswire.com/ — GenBio Inc., a privately owned biotechnology firm developing therapeutic and wellness solutions from uncommon,
scientifically validated natural bioactive compounds, has announced its involvement in the
2026 Asia Bio Partnering Forum, scheduled for September 1–2 at Marina Bay Sands in Singapore.
GenBio’s leadership will be accessible via the partneringONE® platform for private
discussions with pharmaceutical and biotech executives, corporate development groups, and other
relevant strategic entities.
The organization is progressing a multidisciplinary scientific platform aimed at discovering, purifying, and
formulating naturally sourced bioactive compounds with potential uses in combating antimicrobial
resistance, inflammation, and related human health areas.
GenBio’s development pipeline consists of:
• An efflux pump inhibitor program exploring ways to counter bacterial resistance mechanisms
and boost antimicrobial efficacy;
• An antibacterial discovery and drug-repurposing initiative carried out in partnership with Hypha
Discovery in the United Kingdom;
• An anti-inflammatory development program backed by continuing scientific research in Australia; and
• Complementary health and wellness offerings based on the firm’s broader bioactive
compound platform.
“Taking part in the Asia Bio Partnering Forum gives GenBio a key chance to connect directly with international pharmaceutical and biotech decision-makers,” stated Giles Tilley,
Chief Executive Officer of GenBio Inc. “The Asia-Pacific region is becoming ever more vital to worldwide life-sciences
innovation, and Singapore offers an excellent venue for meaningful conversations about GenBio’s research
platform, development initiatives, and long-term strategic outlook.”
GenBio is now gearing up for controlled talks about strategic possibilities concerning the
firm and its scientific portfolio. Qualified parties will gain access to gradually released due
diligence materials following management assessment and the signing of appropriate confidentiality
agreements.
“Partnering systems can become extremely competitive very fast,” remarked Todd D. Sonoga, Director and Chief
Marketing Officer of GenBio Inc. “By introducing GenBio before meeting scheduling begins, we want
prospective strategic parties to have adequate time to grasp our scientific platform, examine our
company profile, and request a meeting with management.”
The Asia Bio Partnering Forum gathers biotech and pharmaceutical executives, corporate
development specialists, institutional investors, and emerging life-sciences firms from throughout the
Asia-Pacific region and global markets. One-on-one meetings are enabled through the
partneringONE platform.
Interested organizations wishing to meet with GenBio can find the company via partneringONE
once the platform goes live on August 4, 2026.
About GenBio Inc.
GenBio Inc. is a U.S.-headquartered biotechnology company creating next-generation antimicrobial, anti-inflammatory, and supplementary health products sourced from rare natural bioactive compounds.
In collaboration with scientific partners in Australia and the United Kingdom, GenBio utilizes systematic
compound identification, biological screening, and development research to convert naturally occurring
bioactivity into commercially viable therapeutic and health prospects.
Developed by Nature. Identified, Refined and Formulated by GenBio
